An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

This early-phase trial is testing a new cancer drug called HCB301 — an engineered protein that combines multiple immune-blocking mechanisms — in adults with advanced solid tumors or classical Hodgkin lymphoma that has stopped responding to prior treatments. **You may be eligible if...** - You are 18 or older - You have an advanced solid tumor that has relapsed or is resistant to all available standard treatments - You have classical Hodgkin lymphoma that has failed at least 2 prior treatment regimens - You have at least one measurable or assessable tumor - You have a good performance status (ECOG 0-1) - You are willing to provide a tumor tissue sample - Your life expectancy is at least 12 weeks **You may NOT be eligible if...** - You have a known allergy to any component of HCB301 - You have active, untreated cancer spread to the brain - You had major surgery or extensive radiation within the past 28 days - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.